ReviewNature reviews. Cancer2026
Cancer theranostics.
Review in Nature reviews. Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Theranostics refers to the inseparable combination of disease diagnosis and therapy, with the former critically guiding the selection, application and outcome of the latter. In oncology, theranostics traditionally encompass radiolabelled peptides for in vivo molecular imaging of receptor expression by cancer cells, followed by radionuclide treatment using the same peptides labelled with β-emitting radioisotopes. Here we provide an overview of the basic principles and current clinical practice of theranostic probes and protocols, and we expand the terminology to include locally and systemically applied nanotheranostics and microtheranostics, as well as imaging-guided surgical interventions. Building on solid progress in target identification, probe design and hardware development, as well as on promising recent results achieved in clinical trials, we foresee a bright and broad future for multiscale theranostics, for the treatment of oncological pathologies and beyond.
Identifiers
42918868What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.